In the Claims:

1. (currently amended) ~~Controlled~~ A controlled dosage aerosol [[with]] comprising at least one medicinal agent, a propellant, and a surface-active agent, said surface-active agent being lecithin, wherein ~~as surface-active agent, characterized in that the~~ said at least one medicinal agent is ~~present~~ in the form of a suspension and ~~that the~~ said propellant is pressure-liquefied isobutane.

2. (currently amended) ~~Controlled~~ The controlled dosage aerosol according to claim 1, ~~characterized in that the~~ wherein said at least one medicinal agent is [[a]] at least one glucocorticoid~~, said glucocorticoid preferably being~~ selected from the group consisting of cortisol, prednisone, prednisolone, methylprednisolone, triamcinolone, prednylidene, fluocortolone, paramethasone, dexamethasone, betamethasone, flunisolide, fluticasone, beclomethasone, budesonide ~~and/or their~~ and anti-asthmatically active derivatives ~~and/or mixtures~~ thereof.

3. (currently amended) ~~Controlled~~ The controlled dosage aerosol according to claim 1, wherein said controlled dosage aerosol ~~or 2, characterized in that it corresponds to the formulation~~ comprises glucocorticoid in the amount of 0.1% - 0.2%, lecithin in the amount of 0.05% - 0.4% and isobutane in the amount of 99.85% - 99.4%.

| | |
|---|---|
| ~~Glucocorticoid~~ | ~~0.1% 0.2%~~ |
| ~~Lecithin~~ | ~~0.05% 0.4%~~ |
| ~~Isobutane~~ | ~~99.85% 99.4%~~ |

4. (currently amended) ~~Controlled~~ The controlled dosage aerosol according to claim 1, wherein said controlled dosage aerosol ~~or 2, characterized in that it corresponds to the formulation~~ comprises glucocorticoid in the amount of 0.5% - 1.0%, lecithin in the amount of 0.25% - 4.0% and isobutane in the amount of 99.75% - 95.0%.

| | |
|---|---|
| ~~Glucocorticoid~~ | ~~0.5% 1.0%~~ |
| ~~Lecithin~~ | ~~0.25% 4.0%~~ |
| ~~Isobutane~~ | ~~99.75% 95.0%~~ |

5. (currently amended) ~~Controlled~~ The controlled dosage aerosol according to claim 1, wherein ~~any one of the preceding claims, characterized in that the~~ said lecithin is soybean lecithin.

6. (currently amended) ~~Controlled~~ The controlled dosage aerosol according to claim 1, wherein said controlled dosage aerosol ~~or 2, characterized in that it corresponds to the~~

~~formulation~~ comprises beclomethasone in the amount of 0.1% - 2.5.0%, soybean lecithin in the amount of 0.05% - 5.0% and isobutane in the amount of 99.85% - 92.5%.

| | |
|---|---|
| ~~Beclomethasone~~ | ~~0.1% 2.5%~~ |
| ~~Soybean lecithin~~ | ~~0.05% 5.0%~~ |
| ~~Isobutane~~ | ~~99.85% 92.5%.~~ |

7. (currently amended) ~~Controlled~~ The controlled dosage aerosol according to claim 1, wherein said controlled dosage aerosol ~~or 2, characterized in that it corresponds to the formulation~~ comprises budesonide in the amount of 0.1% - 2.5.0%, soybean lecithin in the amount of 0.05% - 5.0% and isobutane in the amount of 99.85% - 92.5%.

| | |
|---|---|
| ~~Budesonide~~ | ~~0.1% 2.5%~~ |
| ~~Soybean lecithin~~ | ~~0.05% 5.0%~~ |
| ~~Isobutane~~ | ~~99.85% 92.5%.~~ |

8. (currently amended) ~~Controlled~~ The controlled dosage aerosol according to claim 5, wherein ~~any one of the preceding claims, characterized in that~~ the ratio of glucocorticoid and soybean lecithin is 1:2~~, preferably 1:1, and with particular preference 1:0.5~~.

9. (currently amended) ~~Controlled~~ The controlled dosage aerosol according to claim 1 ~~any one of the preceding claims~~ for treating allergic diseases in humans and animals~~, preferably for inhalation treatment of allergic diseases of the respiratory tract~~.

10. (currently amended) ~~Controlled~~ The controlled dosage aerosol according to claim 1 ~~any one of claims 1 to 8,~~ for treating asthma or allergic rhinitis.

11. (currently amended) ~~Process~~ A process for the production of controlled dosage aerosols according to claim 1, comprising the steps of:

mixing ~~any one of the preceding claims, characterized in that~~ isobutane as a propellant in liquid form, [[and]] lecithin as a surface-active agent in liquid form, and at least one medicinal agent as solid substance to form a ~~are mixed with one other, and that the~~ liquid suspension; and

filling said liquid suspension ~~is filled~~ under pressure into [[the]] a spray tin having a valve ~~provided therefore~~.

12. (currently amended) ~~Process~~ The process according to claim 11, ~~characterized in that after filling in the suspension~~ wherein the temperature of said liquid suspension

after said filling step is between -10 and +10°C.

13. (currently amended) ~~Process~~ The process according to claim 11, further comprising the step of ~~or 12, characterized in that after filling in the suspension, the~~ cleaning said valve of [[the]] said spray tin ~~is cleaned~~ by filling [[the]] said spray tin up with a propellant, said cleaning step being after said filling step.

14. (new) The controlled dosage aerosol according to claim 8, wherein the ratio of glucocorticoid and soybean lecithin is 1:1.

15. (new) The controlled dosage aerosol according to claim 14, wherein the ratio of glucocorticoid and soybean lecithin is 1:0.5.

16. (new) The controlled dosage aerosol according to claim 9 for inhalation treatment of allergic diseases of the respiratory tract.

17. (new) A process for treating allergic diseases comprising administering a controlled dosage aerosol, said aerosol including at least one medicinal agent, a propellant, and lecithin, said lecithin being a surface-active agent, and wherein said at least one medicinal agent is in the form of a suspension and said propellant is pressure-liquefied isobutane.

18. (new) The process for treating allergic diseases according to claim 17, wherein said allergic diseases are selected from the group consisting of allergic rhinitis and asthma.